Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes.

Insulin Japan Psychological insulin resistance Type 2 diabetes mellitus

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 27 03 2019
pubmed: 10 7 2019
medline: 10 7 2019
entrez: 10 7 2019
Statut: ppublish

Résumé

EMOTION was a multinational, noninterventional study surveying current insulin-using adults with type 2 diabetes mellitus (T2D) who were initially reluctant to begin insulin treatment. In this Japanese population subanalysis of EMOTION, we identify the frequency and level of helpfulness of healthcare provider (HCP) actions, and we analyze life events ('actions/events') that assist T2D patients with psychological insulin resistance in the decision to initiate insulin. Participants were selected from Survey Sampling International and their local partners' market research panels in Japan. Quantitative surveys were administered between December 2016 and August 2017 to patients who met the study criteria. Participants were asked whether 45 actions/events occurred, and to rate the level of helpfulness of the actions/events in contributing to their decision to initiate insulin. Among the 594 eligible participating adults in the EMOTION study, 99 were from Japan. Despite initial reluctance to begin insulin treatment, 80.8% of the Japanese participants immediately commenced insulin. Practical demonstrations by HCPs on how to use insulin were rated by participants as most helpful. Examples of such practical demonstrations, reported as helping moderately or a lot, were 'HCP walked patient through the process of exactly how to take insulin' (82.8%), 'HCP showed an insulin pen' (79.7%), and 'HCP helped patient to see how simple it was to inject insulin' (79.1%). This study identifies actions that HCPs can use to assist Japanese patients in deciding whether to initiate insulin. These findings may aid the development of clinical interventions addressing reluctance to begin insulin treatment among Japanese patients with T2D. Eli Lilly and Company and Boehringer Ingelheim. Plain language summary available for this article. The increasing prevalence of type 2 diabetes mellitus (T2D) is a major health concern globally. In Japan, the prevalence of diabetes is predicted to increase over the next decades. Insulin is a hormone which keeps blood glucose levels within the normal range. People with diabetes often require insulin therapy as they do not make sufficient insulin, or the insulin that is produced does not work optimally. Many patients delay insulin therapy due to a variety of factors. Reluctance to begin insulin treatment is known as ‘psychological insulin resistance’ (PIR). Several studies have described recommendations to address PIR, but there is little research regarding effective strategies that help reluctant patients begin insulin. Reports describing PIR among Japanese patients are limited. EMOTION was a multinational study surveying insulin-using adults with T2D and initial PIR. We report a Japanese population subanalysis of EMOTION, identifying factors which help reluctant Japanese patients begin insulin therapy. Our results indicate that healthcare provider (HCP) actions are associated with a patient’s decision to use insulin. Practical demonstrations by HCPs on how to use insulin were reported as most helpful. Reassurance concerning pain of injection, explanations regarding blood glucose numbers and future health, encouragement to make contact in case of any problems, and occurrence of a positive life event were also rated by Japanese participants as being helpful in deciding to commence insulin. This study provides important information on actions that can be used by HCPs to treat Japanese patients with T2D who are reluctant to begin insulin treatment.

Autres résumés

Type: plain-language-summary (eng)
The increasing prevalence of type 2 diabetes mellitus (T2D) is a major health concern globally. In Japan, the prevalence of diabetes is predicted to increase over the next decades. Insulin is a hormone which keeps blood glucose levels within the normal range. People with diabetes often require insulin therapy as they do not make sufficient insulin, or the insulin that is produced does not work optimally. Many patients delay insulin therapy due to a variety of factors. Reluctance to begin insulin treatment is known as ‘psychological insulin resistance’ (PIR). Several studies have described recommendations to address PIR, but there is little research regarding effective strategies that help reluctant patients begin insulin. Reports describing PIR among Japanese patients are limited. EMOTION was a multinational study surveying insulin-using adults with T2D and initial PIR. We report a Japanese population subanalysis of EMOTION, identifying factors which help reluctant Japanese patients begin insulin therapy. Our results indicate that healthcare provider (HCP) actions are associated with a patient’s decision to use insulin. Practical demonstrations by HCPs on how to use insulin were reported as most helpful. Reassurance concerning pain of injection, explanations regarding blood glucose numbers and future health, encouragement to make contact in case of any problems, and occurrence of a positive life event were also rated by Japanese participants as being helpful in deciding to commence insulin. This study provides important information on actions that can be used by HCPs to treat Japanese patients with T2D who are reluctant to begin insulin treatment.

Identifiants

pubmed: 31286432
doi: 10.1007/s13300-019-0664-9
pii: 10.1007/s13300-019-0664-9
pmc: PMC6778551
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1823-1834

Références

Qual Life Res. 2009 Feb;18(1):23-32
pubmed: 19039679
Diabetes Care. 2013 Nov;36(11):3411-7
pubmed: 23877982
Patient. 2014;7(4):437-50
pubmed: 24958464
Diabetes Ther. 2015 Sep;6(3):303-16
pubmed: 26159935
Diabetes Ther. 2018 Apr;9(2):713-726
pubmed: 29520741
Diabetes Care. 2005 Nov;28(11):2673-9
pubmed: 16249538
Diabetes Ther. 2018 Aug;9(4):1415-1419
pubmed: 29808359
Curr Med Res Opin. 2014 Feb;30(2):177-83
pubmed: 24128339
Diabetes Res Clin Pract. 2013 Feb;99(2):174-84
pubmed: 23273515
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
J Clin Transl Endocrinol. 2015 Oct 29;2(4):157-162
pubmed: 29159120
Curr Med Res Opin. 2018 Jun;34(6):1117-1124
pubmed: 29504812
Int J Clin Pract. 2017 Aug;71(8):
pubmed: 28735508
Patient Prefer Adherence. 2016 Jul 25;10:1337-48
pubmed: 27524889
Can J Diabetes. 2016 Feb;40(1):84-94
pubmed: 26827684
J Diabetes Investig. 2018 Mar 26;:
pubmed: 29582574
Curr Med Res Opin. 2016;32(4):681-6
pubmed: 26743676
Acad Med. 2011 Mar;86(3):359-64
pubmed: 21248604
J Diabetes. 2017 Jun;9(6):596-605
pubmed: 27368146
Intern Med. 2016;55(14):1827-30
pubmed: 27432088
Curr Med Res Opin. 2011 Jun;27(6):1169-74
pubmed: 21469914
Diabetes Technol Ther. 2015 Apr;17(4):268-74
pubmed: 25551737
J Diabetes Complications. 2019 Apr;33(4):307-314
pubmed: 30709604
Curr Med Res Opin. 2017 Oct;33(10):1833-1842
pubmed: 28604111
Diabetes Care. 2013 Sep;36(9):2551-8
pubmed: 23735726
Diabet Med. 2013 Jul;30(7):767-77
pubmed: 23711019
Diabetes Educ. 2008 May-Jun;34(3):511-7
pubmed: 18535324
Diabet Med. 2017 Nov;34(11):1599-1602
pubmed: 28905434
Diabetes Care. 2005 Oct;28(10):2543-5
pubmed: 16186296
Diabetes Care. 2010 Apr;33(4):733-5
pubmed: 20086256

Auteurs

Kentaro Okazaki (K)

Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.

Tomotaka Shingaki (T)

Eli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan. shingaki_tomotaka@lilly.com.

Zhihong Cai (Z)

Eli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.

Magaly Perez-Nieves (M)

Eli Lilly and Company, 1555 S Harding Street, Indianapolis, IN, 46221, USA.

Lawrence Fisher (L)

Behavioral Diabetes Institute, 5405 Oberlin Drive Suite 100, San Diego, CA, 92121, USA.

Classifications MeSH